Orphan medicines: special treatment required?: case study 5: Revolade and treatment of chronic ITP

Document type
Case study
Corporate author(s)
2020health (Think tank)
Date of publication
1 November 2012
Health Services
Social welfare
Material type

Download (137KB )

This case study on the drug Revolade and treatment of chronic ITP accompanies a report that examines the evidence to see if there are ways of improving decision making on treatments for people with rare diseases in the NHS. Revolade (eltrombopag) is used in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) and is manufactured by GlaxoSmithKlein (GSK). It’s also used for patients who have had their spleen removed and who do not respond to treatment with medicines such as corticosteroids or immunoglobulins.

Revolade was designated an orphan medicine in 2007. It was approved by European Medicines Agency in 2010.

Related to 2020health

The fear of finding out: identifying psychological barriers to diagnosis in the UK.

This report uses literature data, observations and discussions to frame a new approach to understanding the nature and implications of health-system avoidance by individuals who choose to remain ignorant

Health technologies: are older people interested?

This report finds that the over 65s made up 17% of the population in 2010, up from 15% in 1985, with projections indicating a rise to 23% by 2035.Exponential growth of an aging population indicates

Foresight Project report: a discussion of the potential impact of

This report by the Foresight Project aims to ensure that the optical sector is better equipped to understand directions in  technology, ocular medical developments and demographics in the years up to 2030.

Fat chance? Exploring the evidence on who becomes obese

Current political, economic and social discourse on obesity in the UK illuminates the great complexities and myriad socio-economic considerations that inform people’s health, diets, and health seeking

More items related to this publisher